| Title |
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
|
|---|---|
| Published in |
Neurotherapeutics, January 2017
|
| DOI | 10.1007/s13311-016-0481-z |
| Pubmed ID | |
| Authors |
Scott E Counts, Milos D Ikonomovic, Natosha Mercado, Irving E Vega, Elliott J Mufson |
| Abstract |
The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may reflect the fact that the enrolled participants in clinical trials are already too advanced to derive a clinical benefit. Thus, well-validated biomarkers for the early detection and accurate diagnosis of the preclinical stages of AD will be crucial for therapeutic advancement. The combinatorial use of biomarkers derived from biological fluids, such as cerebrospinal fluid (CSF), with advanced molecular imaging and neuropsychological testing may eventually achieve the diagnostic sensitivity and specificity necessary to identify people in the earliest stages of the disease when drug modification is most likely possible. In this regard, positive amyloid or tau tracer retention on positron emission tomography imaging, low CSF concentrations of the amyloid-β 1-42 peptide, high CSF concentrations in total tau and phospho-tau, mesial temporal lobe atrophy on magnetic resonance imaging, and temporoparietal/precuneus hypometabolism or hypoperfusion on 18F-fluorodeoxyglucose positron emission tomography have all emerged as biomarkers for the progression to AD. However, the ultimate AD biomarker panel will likely involve the inclusion of novel CSF and blood biomarkers more precisely associated with confirmed pathophysiologic mechanisms to improve its reliability for detecting preclinical AD. This review highlights advancements in biological fluid and imaging biomarkers that are moving the field towards achieving the goal of a preclinical detection of AD. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 25% |
| United States | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 346 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | <1% |
| Czechia | 1 | <1% |
| Unknown | 343 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 50 | 14% |
| Student > Master | 48 | 14% |
| Student > Bachelor | 44 | 13% |
| Student > Ph. D. Student | 39 | 11% |
| Student > Doctoral Student | 23 | 7% |
| Other | 49 | 14% |
| Unknown | 93 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 51 | 15% |
| Medicine and Dentistry | 48 | 14% |
| Biochemistry, Genetics and Molecular Biology | 34 | 10% |
| Agricultural and Biological Sciences | 23 | 7% |
| Psychology | 16 | 5% |
| Other | 62 | 18% |
| Unknown | 112 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 September 2022.
All research outputs
#2,472,083
of 25,394,764 outputs
Outputs from Neurotherapeutics
#220
of 1,307 outputs
Outputs of similar age
#48,037
of 421,830 outputs
Outputs of similar age from Neurotherapeutics
#9
of 23 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,307 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 421,830 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.